Perrigo EBITDA Margin 2010-2025 | PRGO
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Perrigo (PRGO) over the last 10 years. The current EBITDA margin for Perrigo as of March 31, 2025 is .
| Perrigo EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-03-31 | $4.34B | $0.55B | 12.68% |
| 2024-12-31 | $4.37B | $0.45B | 10.24% |
| 2024-09-30 | $4.39B | $0.32B | 7.22% |
| 2024-06-30 | $4.43B | $0.31B | 6.95% |
| 2024-03-31 | $4.56B | $0.40B | 8.85% |
| 2023-12-31 | $4.66B | $0.51B | 11.04% |
| 2023-09-30 | $4.65B | $0.57B | 12.31% |
| 2023-06-30 | $4.63B | $0.54B | 11.71% |
| 2023-03-31 | $4.56B | $0.46B | 10.18% |
| 2022-12-31 | $4.45B | $0.42B | 9.37% |
| 2022-09-30 | $4.40B | $0.41B | 9.22% |
| 2022-06-30 | $4.35B | $0.79B | 18.25% |
| 2022-03-31 | $4.20B | $0.67B | 15.89% |
| 2021-12-31 | $4.14B | $0.72B | 17.35% |
| 2021-09-30 | $4.09B | $0.74B | 18.01% |
| 2021-06-30 | $4.05B | $0.40B | 9.91% |
| 2021-03-31 | $4.02B | $0.61B | 15.19% |
| 2020-12-31 | $4.09B | $0.65B | 15.85% |
| 2020-09-30 | $3.39B | $0.58B | 16.99% |
| 2020-06-30 | $3.58B | $0.56B | 15.57% |
| 2020-03-31 | $3.78B | $0.55B | 14.53% |
| 2019-12-31 | $3.87B | $0.57B | 14.65% |
| 2019-09-30 | $4.71B | $0.71B | 15.01% |
| 2019-06-30 | $4.65B | $0.53B | 11.46% |
| 2019-03-31 | $4.69B | $0.59B | 12.48% |
| 2018-12-31 | $4.73B | $0.65B | 13.78% |
| 2018-09-30 | $4.82B | $0.71B | 14.80% |
| 2018-06-30 | $4.92B | $1.00B | 20.32% |
| 2018-03-31 | $4.97B | $1.05B | 21.19% |
| 2017-12-31 | $4.95B | $1.02B | 20.64% |
| 2017-09-30 | $4.99B | $0.39B | 7.79% |
| 2017-06-30 | $5.03B | $-1.24B | -24.70% |
| 2017-03-31 | $5.13B | $-1.21B | -23.54% |
| 2016-12-31 | $5.28B | $-1.57B | -29.69% |
| 2016-09-30 | $2.93B | $-1.77B | -60.30% |
| 2016-06-30 | $2.94B | $-0.13B | -4.46% |
| 2016-03-31 | $3.01B | $-0.42B | -13.94% |
| 2015-12-31 | $2.63B | $-0.04B | -1.67% |
| 2015-09-30 | $4.73B | $1.72B | 36.34% |
| 2015-06-30 | $4.41B | $1.58B | 35.93% |
| 2014-12-31 | $3.03B | $1.68B | 55.38% |
| 2014-09-30 | $2.94B | $1.52B | 51.79% |
| 2013-12-31 | $2.83B | $1.51B | 53.43% |
| 2013-09-30 | $2.74B | $1.39B | 50.84% |
| 2012-12-31 | $2.43B | $1.33B | 54.50% |
| 2012-09-30 | $2.39B | $1.28B | 53.48% |
| 2011-12-31 | $2.26B | $1.17B | 51.97% |
| 2011-09-30 | $2.14B | $1.05B | 48.95% |
| 2010-12-31 | $1.90B | $1.00B | 52.56% |
| 2010-09-30 | $1.76B | $0.85B | 48.44% |
| 2009-12-31 | $1.62B | $0.81B | 50.06% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.785B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $229.693B | 27.62 |
| Boston Scientific (BSX) | United States | $152.679B | 38.22 |
| Stryker (SYK) | United States | $148.653B | 31.08 |
| EssilorLuxottica (ESLOY) | France | $131.422B | 0.00 |
| Medtronic (MDT) | Ireland | $115.326B | 16.35 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.666B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.744B | 25.54 |
| ResMed (RMD) | United States | $37.302B | 28.02 |
| Agilent Technologies (A) | United States | $35.020B | 22.83 |
| GE HealthCare Technologies (GEHC) | United States | $34.401B | 16.33 |
| Terumo (TRUMY) | Japan | $24.607B | 31.96 |
| Koninklijke Philips (PHG) | Netherlands | $23.139B | 16.24 |
| Insulet (PODD) | United States | $20.361B | 79.92 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.556B | 11.92 |
| Baxter (BAX) | United States | $14.728B | 11.00 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.262B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.993B | 24.33 |
| Lantheus Holdings (LNTH) | United States | $5.626B | 14.19 |
| Prestige Consumer Healthcare (PBH) | United States | $3.780B | 16.89 |
| Haemonetics (HAE) | United States | $3.628B | 16.52 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.424B | 28.45 |
| ICU Medical (ICUI) | United States | $3.253B | 23.99 |
| QuidelOrtho (QDEL) | United States | $2.052B | 14.11 |
| LeMaitre Vascular (LMAT) | United States | $1.891B | 42.26 |
| AtriCure (ATRC) | United States | $1.521B | 0.00 |
| Acuren (TIC) | United States | $1.395B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.389B | 31.24 |
| Phibro Animal Health (PAHC) | United States | $1.248B | 15.96 |
| AdaptHealth (AHCO) | United States | $1.244B | 12.63 |
| Neogen (NEOG) | United States | $1.170B | 14.97 |
| BioLife Solutions (BLFS) | United States | $1.050B | 0.00 |
| InMode (INMD) | Israel | $0.930B | 9.37 |
| Curaleaf Holdings (CURLF) | Canada | $0.771B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $0.766B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.695B | 0.00 |
| Owens & Minor (OMI) | United States | $0.627B | 5.21 |
| Evolus (EOLS) | United States | $0.611B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.584B | 0.00 |
| CeriBell (CBLL) | United States | $0.583B | 0.00 |
| Valneva SE (VALN) | France | $0.517B | 0.00 |
| Surmodics (SRDX) | United States | $0.441B | 0.00 |
| SNDL (SNDL) | Canada | $0.365B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.349B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.337B | 12.38 |
| Cresco Labs (CRLBF) | United States | $0.323B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.298B | 0.00 |
| Quanterix (QTRX) | United States | $0.294B | 0.00 |
| Cerus (CERS) | United States | $0.277B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 22.47 |
| Sanara MedTech (SMTI) | United States | $0.258B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.252B | 74.83 |
| ZimVie (ZIMV) | United States | $0.251B | 11.39 |
| Verano Holdings (VRNOF) | United States | $0.235B | 0.00 |
| Brainsway (BWAY) | Israel | $0.233B | 61.55 |
| OraSure Technologies (OSUR) | United States | $0.232B | 0.00 |
| Biote (BTMD) | United States | $0.223B | 6.28 |
| Omeros (OMER) | United States | $0.214B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.208B | 0.00 |
| Organigram Global (OGI) | Canada | $0.194B | 0.00 |
| High Tide (HITI) | Canada | $0.191B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.185B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.183B | 14.93 |
| Vireo Growth (VREOF) | United States | $0.163B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.122B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.117B | 0.00 |
| MacroGenics (MGNX) | United States | $0.102B | 0.00 |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.098B | 12.68 |
| Jushi Holdings (JUSHF) | United States | $0.090B | 0.00 |
| Veru (VERU) | United States | $0.088B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.081B | 0.00 |
| Apyx Medical (APYX) | United States | $0.079B | 0.00 |
| Agape ATP (ATPC) | $0.074B | 0.00 | |
| InterCure (INCR) | Israel | $0.071B | 0.00 |
| Zynex (ZYXI) | United States | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.039B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| Nephros (NEPH) | United States | $0.038B | 51.43 |
| United-Guardian (UG) | United States | $0.037B | 12.89 |
| Safety Shot (SHOT) | United States | $0.034B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |